VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate

NEXT STORY
Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome (“IBS”) Diagnostic-Guided Therapy clinical trial
PREV STORY
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress

NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...

author_avatar
NASDAQ Market News

Disposable Negative Pressure Wound Therapy Devices (NPWT) Market is anticipated to Witness a CAGR of 10.6% over the Forecast Period of 2017 and 2027

VALLEY COTTAGE, NY, Feb. 26, 2018 (GLOBE NEWSWIRE) -- In the report published by ...

author_avatar
NASDAQ Market News

Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial

NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today ...

author_avatar
NASDAQ Market News